# To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions

> **NCT00913848** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 30 (actual)

## Conditions studied

- Epilepsy
- Bipolar Disorder

## Interventions

- **DRUG:** Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
- **DRUG:** Depakote 500 mg DR Tablets (Abbott Laboratories, USA)

## Key facts

- **NCT ID:** NCT00913848
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913848, "To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00913848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*